Risk of COVID-19 death in adults who received booster COVID-19 vaccinations in England

The emergence of the COVID-19 vaccination has been critical in changing the course of the COVID-19 pandemic. To ensure protection remains high in vulnerable groups booster vaccinations in the UK have been targeted based on age and clinical vulnerabilities. We undertook a national retrospective cohor...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Nature communications Ročník 15; číslo 1; s. 398 - 6
Hlavní autoři: Ward, Isobel L., Robertson, Chris, Agrawal, Utkarsh, Patterson, Lynsey, Bradley, Declan T., Shi, Ting, de Lusignan, Simon, Hobbs, F. D. Richard, Sheikh, Aziz, Nafilyan, Vahé
Médium: Journal Article
Jazyk:angličtina
Vydáno: London Nature Publishing Group UK 16.01.2024
Nature Publishing Group
Nature Portfolio
Témata:
631/326/596/2562
631/326/596/4130
692/499
692/699/255/2514
Adult
Adults
At risk populations
Autoimmune diseases
Blood
Blood cancer
Bone cancer
Bone marrow
Cancer
Chronic conditions
Cirrhosis
COVID-19
COVID-19 - epidemiology
COVID-19 - prevention & control
COVID-19 Vaccines
Cystic fibrosis
Death
Dementia disorders
Down's syndrome
Electronic health records
Electronic medical records
England - epidemiology
Humanities and Social Sciences
Humans
Huntingtons disease
Hypertension
Hypotension
Immunization
Kidney diseases
Liver Cirrhosis
Lung cancer
Lung diseases
Mortality
Motor neuron diseases
Mouth Neoplasms
Movement disorders
multidisciplinary
Multiple sclerosis
Myasthenia gravis
Neurodegenerative diseases
Neuromuscular junctions
Oral cancer
Pandemics
Parkinson's disease
Retrospective Studies
Rheumatoid arthritis
Risk
Science
Science (multidisciplinary)
Systemic lupus erythematosus
England
United Kingdom > UK
ISSN:2041-1723, 2041-1723
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract The emergence of the COVID-19 vaccination has been critical in changing the course of the COVID-19 pandemic. To ensure protection remains high in vulnerable groups booster vaccinations in the UK have been targeted based on age and clinical vulnerabilities. We undertook a national retrospective cohort study using data from the 2021 Census linked to electronic health records. We fitted cause-specific Cox models to examine the association between health conditions and the risk of COVID-19 death and all-other-cause death for adults aged 50-100-years in England vaccinated with a booster in autumn 2022. Here we show, having learning disabilities or Down Syndrome (hazard ratio=5.07;95% confidence interval=3.69-6.98), pulmonary hypertension or fibrosis (2.88;2.43-3.40), motor neuron disease, multiple sclerosis, myasthenia or Huntington’s disease (2.94, 1.82-4.74), cancer of blood and bone marrow (3.11;2.72-3.56), Parkinson’s disease (2.74;2.34-3.20), lung or oral cancer (2.57;2.04 to 3.24), dementia (2.64;2.46 to 2.83) or liver cirrhosis (2.65;1.95 to 3.59) was associated with an increased risk of COVID-19 death. Individuals with cancer of the blood or bone marrow, chronic kidney disease, cystic fibrosis, pulmonary hypotension or fibrosis, or rheumatoid arthritis or systemic lupus erythematosus had a significantly higher risk of COVID-19 death relative to other causes of death compared with individuals who did not have diagnoses. Policy makers should continue to priorities vulnerable groups for subsequent COVID-19 booster doses to minimise the risk of COVID-19 death. Ward et al. utilise electronic health records to identify groups of adults (who had received a second booster dose of a COVID-19 vaccine) at elevated risk of COVID-19 death.
AbstractList The emergence of the COVID-19 vaccination has been critical in changing the course of the COVID-19 pandemic. To ensure protection remains high in vulnerable groups booster vaccinations in the UK have been targeted based on age and clinical vulnerabilities. We undertook a national retrospective cohort study using data from the 2021 Census linked to electronic health records. We fitted cause-specific Cox models to examine the association between health conditions and the risk of COVID-19 death and all-other-cause death for adults aged 50-100-years in England vaccinated with a booster in autumn 2022. Here we show, having learning disabilities or Down Syndrome (hazard ratio=5.07;95% confidence interval=3.69-6.98), pulmonary hypertension or fibrosis (2.88;2.43-3.40), motor neuron disease, multiple sclerosis, myasthenia or Huntington’s disease (2.94, 1.82-4.74), cancer of blood and bone marrow (3.11;2.72-3.56), Parkinson’s disease (2.74;2.34-3.20), lung or oral cancer (2.57;2.04 to 3.24), dementia (2.64;2.46 to 2.83) or liver cirrhosis (2.65;1.95 to 3.59) was associated with an increased risk of COVID-19 death. Individuals with cancer of the blood or bone marrow, chronic kidney disease, cystic fibrosis, pulmonary hypotension or fibrosis, or rheumatoid arthritis or systemic lupus erythematosus had a significantly higher risk of COVID-19 death relative to other causes of death compared with individuals who did not have diagnoses. Policy makers should continue to priorities vulnerable groups for subsequent COVID-19 booster doses to minimise the risk of COVID-19 death.Ward et al. utilise electronic health records to identify groups of adults (who had received a second booster dose of a COVID-19 vaccine) at elevated risk of COVID-19 death.
The emergence of the COVID-19 vaccination has been critical in changing the course of the COVID-19 pandemic. To ensure protection remains high in vulnerable groups booster vaccinations in the UK have been targeted based on age and clinical vulnerabilities. We undertook a national retrospective cohort study using data from the 2021 Census linked to electronic health records. We fitted cause-specific Cox models to examine the association between health conditions and the risk of COVID-19 death and all-other-cause death for adults aged 50-100-years in England vaccinated with a booster in autumn 2022. Here we show, having learning disabilities or Down Syndrome (hazard ratio=5.07;95% confidence interval=3.69-6.98), pulmonary hypertension or fibrosis (2.88;2.43-3.40), motor neuron disease, multiple sclerosis, myasthenia or Huntington's disease (2.94, 1.82-4.74), cancer of blood and bone marrow (3.11;2.72-3.56), Parkinson's disease (2.74;2.34-3.20), lung or oral cancer (2.57;2.04 to 3.24), dementia (2.64;2.46 to 2.83) or liver cirrhosis (2.65;1.95 to 3.59) was associated with an increased risk of COVID-19 death. Individuals with cancer of the blood or bone marrow, chronic kidney disease, cystic fibrosis, pulmonary hypotension or fibrosis, or rheumatoid arthritis or systemic lupus erythematosus had a significantly higher risk of COVID-19 death relative to other causes of death compared with individuals who did not have diagnoses. Policy makers should continue to priorities vulnerable groups for subsequent COVID-19 booster doses to minimise the risk of COVID-19 death.
The emergence of the COVID-19 vaccination has been critical in changing the course of the COVID-19 pandemic. To ensure protection remains high in vulnerable groups booster vaccinations in the UK have been targeted based on age and clinical vulnerabilities. We undertook a national retrospective cohort study using data from the 2021 Census linked to electronic health records. We fitted cause-specific Cox models to examine the association between health conditions and the risk of COVID-19 death and all-other-cause death for adults aged 50-100-years in England vaccinated with a booster in autumn 2022. Here we show, having learning disabilities or Down Syndrome (hazard ratio=5.07;95% confidence interval=3.69-6.98), pulmonary hypertension or fibrosis (2.88;2.43-3.40), motor neuron disease, multiple sclerosis, myasthenia or Huntington's disease (2.94, 1.82-4.74), cancer of blood and bone marrow (3.11;2.72-3.56), Parkinson's disease (2.74;2.34-3.20), lung or oral cancer (2.57;2.04 to 3.24), dementia (2.64;2.46 to 2.83) or liver cirrhosis (2.65;1.95 to 3.59) was associated with an increased risk of COVID-19 death. Individuals with cancer of the blood or bone marrow, chronic kidney disease, cystic fibrosis, pulmonary hypotension or fibrosis, or rheumatoid arthritis or systemic lupus erythematosus had a significantly higher risk of COVID-19 death relative to other causes of death compared with individuals who did not have diagnoses. Policy makers should continue to priorities vulnerable groups for subsequent COVID-19 booster doses to minimise the risk of COVID-19 death.The emergence of the COVID-19 vaccination has been critical in changing the course of the COVID-19 pandemic. To ensure protection remains high in vulnerable groups booster vaccinations in the UK have been targeted based on age and clinical vulnerabilities. We undertook a national retrospective cohort study using data from the 2021 Census linked to electronic health records. We fitted cause-specific Cox models to examine the association between health conditions and the risk of COVID-19 death and all-other-cause death for adults aged 50-100-years in England vaccinated with a booster in autumn 2022. Here we show, having learning disabilities or Down Syndrome (hazard ratio=5.07;95% confidence interval=3.69-6.98), pulmonary hypertension or fibrosis (2.88;2.43-3.40), motor neuron disease, multiple sclerosis, myasthenia or Huntington's disease (2.94, 1.82-4.74), cancer of blood and bone marrow (3.11;2.72-3.56), Parkinson's disease (2.74;2.34-3.20), lung or oral cancer (2.57;2.04 to 3.24), dementia (2.64;2.46 to 2.83) or liver cirrhosis (2.65;1.95 to 3.59) was associated with an increased risk of COVID-19 death. Individuals with cancer of the blood or bone marrow, chronic kidney disease, cystic fibrosis, pulmonary hypotension or fibrosis, or rheumatoid arthritis or systemic lupus erythematosus had a significantly higher risk of COVID-19 death relative to other causes of death compared with individuals who did not have diagnoses. Policy makers should continue to priorities vulnerable groups for subsequent COVID-19 booster doses to minimise the risk of COVID-19 death.
The emergence of the COVID-19 vaccination has been critical in changing the course of the COVID-19 pandemic. To ensure protection remains high in vulnerable groups booster vaccinations in the UK have been targeted based on age and clinical vulnerabilities. We undertook a national retrospective cohort study using data from the 2021 Census linked to electronic health records. We fitted cause-specific Cox models to examine the association between health conditions and the risk of COVID-19 death and all-other-cause death for adults aged 50-100-years in England vaccinated with a booster in autumn 2022. Here we show, having learning disabilities or Down Syndrome (hazard ratio=5.07;95% confidence interval=3.69-6.98), pulmonary hypertension or fibrosis (2.88;2.43-3.40), motor neuron disease, multiple sclerosis, myasthenia or Huntington’s disease (2.94, 1.82-4.74), cancer of blood and bone marrow (3.11;2.72-3.56), Parkinson’s disease (2.74;2.34-3.20), lung or oral cancer (2.57;2.04 to 3.24), dementia (2.64;2.46 to 2.83) or liver cirrhosis (2.65;1.95 to 3.59) was associated with an increased risk of COVID-19 death. Individuals with cancer of the blood or bone marrow, chronic kidney disease, cystic fibrosis, pulmonary hypotension or fibrosis, or rheumatoid arthritis or systemic lupus erythematosus had a significantly higher risk of COVID-19 death relative to other causes of death compared with individuals who did not have diagnoses. Policy makers should continue to priorities vulnerable groups for subsequent COVID-19 booster doses to minimise the risk of COVID-19 death. Ward et al. utilise electronic health records to identify groups of adults (who had received a second booster dose of a COVID-19 vaccine) at elevated risk of COVID-19 death.
Abstract The emergence of the COVID-19 vaccination has been critical in changing the course of the COVID-19 pandemic. To ensure protection remains high in vulnerable groups booster vaccinations in the UK have been targeted based on age and clinical vulnerabilities. We undertook a national retrospective cohort study using data from the 2021 Census linked to electronic health records. We fitted cause-specific Cox models to examine the association between health conditions and the risk of COVID-19 death and all-other-cause death for adults aged 50-100-years in England vaccinated with a booster in autumn 2022. Here we show, having learning disabilities or Down Syndrome (hazard ratio=5.07;95% confidence interval=3.69-6.98), pulmonary hypertension or fibrosis (2.88;2.43-3.40), motor neuron disease, multiple sclerosis, myasthenia or Huntington’s disease (2.94, 1.82-4.74), cancer of blood and bone marrow (3.11;2.72-3.56), Parkinson’s disease (2.74;2.34-3.20), lung or oral cancer (2.57;2.04 to 3.24), dementia (2.64;2.46 to 2.83) or liver cirrhosis (2.65;1.95 to 3.59) was associated with an increased risk of COVID-19 death. Individuals with cancer of the blood or bone marrow, chronic kidney disease, cystic fibrosis, pulmonary hypotension or fibrosis, or rheumatoid arthritis or systemic lupus erythematosus had a significantly higher risk of COVID-19 death relative to other causes of death compared with individuals who did not have diagnoses. Policy makers should continue to priorities vulnerable groups for subsequent COVID-19 booster doses to minimise the risk of COVID-19 death.
ArticleNumber 398
Author Ward, Isobel L.
Nafilyan, Vahé
Bradley, Declan T.
Robertson, Chris
de Lusignan, Simon
Patterson, Lynsey
Hobbs, F. D. Richard
Sheikh, Aziz
Agrawal, Utkarsh
Shi, Ting
Author_xml – sequence: 1
  givenname: Isobel L.
  surname: Ward
  fullname: Ward, Isobel L.
  email: Isobel.Ward@ons.gov.uk
  organization: Office for National Statistics
– sequence: 2
  givenname: Chris
  orcidid: 0000-0001-6848-5241
  surname: Robertson
  fullname: Robertson, Chris
  organization: Department of Mathematics and Statistics, Strathclyde University, Public Health Scotland
– sequence: 3
  givenname: Utkarsh
  surname: Agrawal
  fullname: Agrawal, Utkarsh
  organization: Nuffield Department of Primary Care Health Sciences, University of Oxford
– sequence: 4
  givenname: Lynsey
  surname: Patterson
  fullname: Patterson, Lynsey
  organization: Centre for Public Health, Queen’s University Belfast, Public Health Agency
– sequence: 5
  givenname: Declan T.
  orcidid: 0000-0003-1468-1823
  surname: Bradley
  fullname: Bradley, Declan T.
  organization: Centre for Public Health, Queen’s University Belfast, Public Health Agency
– sequence: 6
  givenname: Ting
  orcidid: 0000-0002-4101-4535
  surname: Shi
  fullname: Shi, Ting
  organization: Usher Institute, University of Edinburgh
– sequence: 7
  givenname: Simon
  orcidid: 0000-0002-8553-2641
  surname: de Lusignan
  fullname: de Lusignan, Simon
  organization: Nuffield Department of Primary Care Health Sciences, University of Oxford
– sequence: 8
  givenname: F. D. Richard
  surname: Hobbs
  fullname: Hobbs, F. D. Richard
  organization: Nuffield Department of Primary Care Health Sciences, University of Oxford, NIHR Applied Research Collaboration, Oxford Thames Valley
– sequence: 9
  givenname: Aziz
  orcidid: 0000-0001-7022-3056
  surname: Sheikh
  fullname: Sheikh, Aziz
  organization: Usher Institute, University of Edinburgh
– sequence: 10
  givenname: Vahé
  orcidid: 0000-0003-0160-217X
  surname: Nafilyan
  fullname: Nafilyan, Vahé
  organization: Office for National Statistics
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38228613$$D View this record in MEDLINE/PubMed
BookMark eNp9kktvEzEUhS1UREvoH2CBRmLDZsCvmbFXCIUWIlWqhKBby487icPELvZMKP--blL6WtQbW_Z3jq-vz2t0EGIAhN4S_JFgJj5lTnjb1ZiymnPatfXVC3REMSc16Sg7eLA-RMc5r3EZTBLB-St0yASloiXsCF388Pl3Fftqfn6x-FoTWTnQ46ryodJuGsZc_V3FKoEFvwVXmRjzCOme3mprfdCjjyHfiE7CctDBvUEvez1kOL6dZ-jX6cnP-ff67PzbYv7lrLYNJ2PdOyqdNBZMy6nrGSa0odoZYm2rDWZtZ7hwtgfoOs0FmL7TwjWArcQchGUztNj7uqjX6jL5jU7_VNRe7TZiWiqdRm8HUExbrLUlrteO90SYxjgnrGl63TAroXh93ntdTmYDzkIYkx4emT4-CX6llnGrCO4kaUs7Z-jDrUOKfybIo9r4bGEoHYE4ZUUlaaQkTHYFff8EXccphdKrHcU5b5go1LuHJd3V8v__CkD3gE0x5wT9HUKwusmJ2udElZyoXU7UVRGJJyLrx90Xlmf54Xkp20tzuScsId2X_YzqGr3o0nk
CitedBy_id crossref_primary_10_1016_j_clinthera_2025_07_006
crossref_primary_10_3389_fmed_2025_1554100
crossref_primary_10_1007_s40615_024_02060_7
crossref_primary_10_3390_vaccines12091064
crossref_primary_10_1016_j_jiph_2024_05_007
crossref_primary_10_1038_s41598_025_02784_4
crossref_primary_10_1177_09612033241309845
Cites_doi 10.1016/S0140-6736(22)01656-7
10.1001/jamanetworkopen.2022.33446
10.1371/journal.pone.0270801
10.1093/ije/dyac199
10.1016/S2213-2600(21)00380-5
10.1016/S2589-7500(21)00080-7
10.1016/j.vaccine.2023.02.038
10.1136/thoraxjnl-2021-217580
ContentType Journal Article
Copyright Crown 2024
2024. Crown.
Crown 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: Crown 2024
– notice: 2024. Crown.
– notice: Crown 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QL
7QP
7QR
7SN
7SS
7ST
7T5
7T7
7TM
7TO
7X7
7XB
88E
8AO
8FD
8FE
8FG
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
ARAPS
AZQEC
BBNVY
BENPR
BGLVJ
BHPHI
C1K
CCPQU
COVID
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
LK8
M0S
M1P
M7P
P5Z
P62
P64
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
RC3
SOI
7X8
5PM
DOA
DOI 10.1038/s41467-023-44276-x
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Bacteriology Abstracts (Microbiology B)
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Ecology Abstracts
Entomology Abstracts (Full archive)
Environment Abstracts
Immunology Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Technology Research Database
ProQuest SciTech Collection
ProQuest Technology Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability (subscription)
ProQuest Central UK/Ireland
Advanced Technologies & Computer Science Collection
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Technology collection
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
Coronavirus Research Database
ProQuest Central
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Health & Medical Collection (Alumni Edition)
PQ Medical Database
ProQuest Biological Science
AAdvanced Technologies & Aerospace Database (subscription)
ProQuest Advanced Technologies & Aerospace Collection
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
Genetics Abstracts
Environment Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
ProQuest Advanced Technologies & Aerospace Collection
ProQuest Central Essentials
Nucleic Acids Abstracts
SciTech Premium Collection
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Health Research Premium Collection
Natural Science Collection
Health & Medical Research Collection
Biological Science Collection
Chemoreception Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Advanced Technologies & Aerospace Collection
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
Biological Science Database
Ecology Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Entomology Abstracts
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
Calcium & Calcified Tissue Abstracts
ProQuest One Academic (New)
Technology Collection
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central
ProQuest Health & Medical Research Collection
Genetics Abstracts
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
AIDS and Cancer Research Abstracts
ProQuest SciTech Collection
Advanced Technologies & Aerospace Database
ProQuest Medical Library
Immunology Abstracts
Environment Abstracts
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database
MEDLINE
MEDLINE - Academic



CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: PIMPY
  name: Publicly Available Content Database
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2041-1723
EndPage 6
ExternalDocumentID oai_doaj_org_article_3ac0aac1dfad4f18b5bdd8cb5fa53c9e
PMC10791661
38228613
10_1038_s41467_023_44276_x
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations England
United Kingdom--UK
GeographicLocations_xml – name: England
– name: United Kingdom--UK
GrantInformation_xml – fundername: Medical Research Council
  grantid: MC_PC_20060
– fundername: Medical Research Council
  grantid: MC_PC_19004
– fundername: Medical Research Council
  grantid: MC_PC_19075
GroupedDBID ---
0R~
39C
3V.
53G
5VS
70F
7X7
88E
8AO
8FE
8FG
8FH
8FI
8FJ
AAHBH
AAJSJ
ABUWG
ACGFO
ACGFS
ACIWK
ACMJI
ACPRK
ACSMW
ADBBV
ADFRT
ADMLS
ADRAZ
AENEX
AEUYN
AFKRA
AFRAH
AHMBA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMTXH
AOIJS
ARAPS
ASPBG
AVWKF
AZFZN
BBNVY
BCNDV
BENPR
BGLVJ
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
EBLON
EBS
EE.
EMOBN
F5P
FEDTE
FYUFA
GROUPED_DOAJ
HCIFZ
HMCUK
HVGLF
HYE
HZ~
KQ8
LGEZI
LK8
LOTEE
M1P
M48
M7P
M~E
NADUK
NAO
NXXTH
O9-
OK1
P2P
P62
PIMPY
PQQKQ
PROAC
PSQYO
RNS
RNT
RNTTT
RPM
SNYQT
SV3
TSG
UKHRP
AASML
AAYXX
AFFHD
CITATION
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
AARCD
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7QP
7QR
7SN
7SS
7ST
7T5
7T7
7TM
7TO
7XB
8FD
8FK
AZQEC
C1K
COVID
DWQXO
FR3
GNUQQ
H94
K9.
P64
PKEHL
PQEST
PQUKI
PRINS
RC3
SOI
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c541t-fd29d9bceb642df301252adb1cc6ab0367b48dcfee77a48ebf7a8d5e0c904e8c3
IEDL.DBID M7P
ISICitedReferencesCount 7
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001147728500020&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2041-1723
IngestDate Fri Oct 03 12:50:32 EDT 2025
Tue Nov 04 02:05:58 EST 2025
Thu Sep 04 15:10:03 EDT 2025
Tue Oct 07 07:45:37 EDT 2025
Sun Aug 10 01:31:36 EDT 2025
Sat Nov 29 03:29:45 EST 2025
Tue Nov 18 21:08:58 EST 2025
Fri Feb 21 02:37:27 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License 2024. Crown.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c541t-fd29d9bceb642df301252adb1cc6ab0367b48dcfee77a48ebf7a8d5e0c904e8c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-8553-2641
0000-0001-6848-5241
0000-0003-1468-1823
0000-0001-7022-3056
0000-0003-0160-217X
0000-0002-4101-4535
OpenAccessLink https://www.proquest.com/docview/2915444538?pq-origsite=%requestingapplication%
PMID 38228613
PQID 2915444538
PQPubID 546298
PageCount 6
ParticipantIDs doaj_primary_oai_doaj_org_article_3ac0aac1dfad4f18b5bdd8cb5fa53c9e
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10791661
proquest_miscellaneous_2915991397
proquest_journals_2915444538
pubmed_primary_38228613
crossref_primary_10_1038_s41467_023_44276_x
crossref_citationtrail_10_1038_s41467_023_44276_x
springer_journals_10_1038_s41467_023_44276_x
PublicationCentury 2000
PublicationDate 2024-01-16
PublicationDateYYYYMMDD 2024-01-16
PublicationDate_xml – month: 01
  year: 2024
  text: 2024-01-16
  day: 16
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Nature communications
PublicationTitleAbbrev Nat Commun
PublicationTitleAlternate Nat Commun
PublicationYear 2024
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Nafilyan, Ward, Robertson, Sheikh (CR8) 2022; 5
CR4
CR3
Agrawal (CR6) 2021; 9
CR5
CR7
CR18
Kerr (CR1) 2023; 52
CR16
CR15
CR14
CR13
CR12
Nafilyan (CR17) 2021; 3
CR10
Smits (CR9) 2023; 41
Agrawal (CR2) 2022; 400
Berec (CR11) 2022; 17
44276_CR7
44276_CR16
V Nafilyan (44276_CR17) 2021; 3
44276_CR5
44276_CR15
44276_CR14
44276_CR18
U Agrawal (44276_CR2) 2022; 400
44276_CR3
PD Smits (44276_CR9) 2023; 41
44276_CR4
U Agrawal (44276_CR6) 2021; 9
V Nafilyan (44276_CR8) 2022; 5
S Kerr (44276_CR1) 2023; 52
44276_CR13
44276_CR12
44276_CR10
L Berec (44276_CR11) 2022; 17
References_xml – ident: CR18
– volume: 400
  start-page: 1305
  year: 2022
  end-page: 1320
  ident: CR2
  article-title: Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales
  publication-title: Lancet
  doi: 10.1016/S0140-6736(22)01656-7
– volume: 5
  start-page: E2233446
  year: 2022
  ident: CR8
  article-title: Evaluation of risk factors for postbooster Omicron COVID-19 deaths in England
  publication-title: JAMA Netw. Open
  doi: 10.1001/jamanetworkopen.2022.33446
– volume: 17
  start-page: 1
  year: 2022
  end-page: 13
  ident: CR11
  article-title: Protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in Czechia
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0270801
– volume: 52
  start-page: 22
  year: 2023
  end-page: 31
  ident: CR1
  article-title: Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled target trial study of 12.9 million individuals in England, Northern Ireland, Scotland and Wales
  publication-title: Int. J. Epidemiol.
  doi: 10.1093/ije/dyac199
– ident: CR3
– ident: CR4
– ident: CR14
– ident: CR15
– ident: CR16
– ident: CR12
– ident: CR13
– ident: CR10
– volume: 9
  start-page: 1439
  year: 2021
  end-page: 1449
  ident: CR6
  article-title: COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2.57 million people in Scotland (EAVE II): a prospective cohort study,
  publication-title: Lancet Respir. Med.
  doi: 10.1016/S2213-2600(21)00380-5
– ident: CR5
– ident: CR7
– volume: 3
  start-page: e425
  year: 2021
  end-page: e433
  ident: CR17
  article-title: An external validation of the QCovid risk prediction algorithm for risk of mortality from COVID-19 in adults: a national validation cohort study in England
  publication-title: Lancet Digit. Heal.
  doi: 10.1016/S2589-7500(21)00080-7
– volume: 41
  start-page: 2447
  year: 2023
  end-page: 2455
  ident: CR9
  article-title: Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2023.02.038
– volume: 17
  start-page: 1
  year: 2022
  ident: 44276_CR11
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0270801
– volume: 400
  start-page: 1305
  year: 2022
  ident: 44276_CR2
  publication-title: Lancet
  doi: 10.1016/S0140-6736(22)01656-7
– ident: 44276_CR4
– ident: 44276_CR3
– volume: 41
  start-page: 2447
  year: 2023
  ident: 44276_CR9
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2023.02.038
– ident: 44276_CR5
– ident: 44276_CR18
  doi: 10.1136/thoraxjnl-2021-217580
– ident: 44276_CR7
– ident: 44276_CR10
– volume: 9
  start-page: 1439
  year: 2021
  ident: 44276_CR6
  publication-title: Lancet Respir. Med.
  doi: 10.1016/S2213-2600(21)00380-5
– volume: 3
  start-page: e425
  year: 2021
  ident: 44276_CR17
  publication-title: Lancet Digit. Heal.
  doi: 10.1016/S2589-7500(21)00080-7
– volume: 52
  start-page: 22
  year: 2023
  ident: 44276_CR1
  publication-title: Int. J. Epidemiol.
  doi: 10.1093/ije/dyac199
– ident: 44276_CR12
– ident: 44276_CR13
– ident: 44276_CR14
– ident: 44276_CR15
– ident: 44276_CR16
– volume: 5
  start-page: E2233446
  year: 2022
  ident: 44276_CR8
  publication-title: JAMA Netw. Open
  doi: 10.1001/jamanetworkopen.2022.33446
SSID ssj0000391844
Score 2.4725435
Snippet The emergence of the COVID-19 vaccination has been critical in changing the course of the COVID-19 pandemic. To ensure protection remains high in vulnerable...
Abstract The emergence of the COVID-19 vaccination has been critical in changing the course of the COVID-19 pandemic. To ensure protection remains high in...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 398
SubjectTerms 631/326/596/2562
631/326/596/4130
692/499
692/699/255/2514
Adult
Adults
At risk populations
Autoimmune diseases
Blood
Blood cancer
Bone cancer
Bone marrow
Cancer
Chronic conditions
Cirrhosis
COVID-19
COVID-19 - epidemiology
COVID-19 - prevention & control
COVID-19 Vaccines
Cystic fibrosis
Death
Dementia disorders
Down's syndrome
Electronic health records
Electronic medical records
England - epidemiology
Humanities and Social Sciences
Humans
Huntingtons disease
Hypertension
Hypotension
Immunization
Kidney diseases
Liver Cirrhosis
Lung cancer
Lung diseases
Mortality
Motor neuron diseases
Mouth Neoplasms
Movement disorders
multidisciplinary
Multiple sclerosis
Myasthenia gravis
Neurodegenerative diseases
Neuromuscular junctions
Oral cancer
Pandemics
Parkinson's disease
Retrospective Studies
Rheumatoid arthritis
Risk
Science
Science (multidisciplinary)
Systemic lupus erythematosus
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB6hCiQuqJRXSqmMxA2sxomd2EcoVCChghCserP8VCNQtmq2D_49Yye77fK8cI1taTSexzex_Q3AM18FKWsmKG-CpVxES03kgfrSxPRUNIhMpTR73x4eyqMj9fFaq690J2ykBx4Vt1cbVxrjmI_G88ikFdZ76ayIRtROhRR9y1ZdK6ZyDK4Vli58eiVT1nJv4DkmYIqinFdtQy_XMlEm7P8dyvz1suRPJ6Y5ER1swp0JQZKXo-R34Ubot-DW2FPy-z2YfeqGr2Qeyf6H2bvXlCniE8ojXU8y18ZALo7nBONcwDjnCYLsRJVwNfvcONeNvwiHtGjq8nEfvhy8-bz_lk7NE6gTnC1o9JXyyrpgscLwEf24EpXxljnXGIt5q7VcehdDaFvDZbCxNdKLUDpV8iBd_QA2-nkfHgEJ3voKy4paCdwCqSwz0SvjImLHxktRAFsqUruJWTw1uPim8wl3LfWofI3K11n5-rKA56s1JyOvxl9nv0r7s5qZOLHzB7QUPVmK_pelFLCz3F09OeqgK5XoiDiG_QKerobRxdK5ienD_GycoxJ9alvAw9EYVpLUCLAkQqIC5JqZrIm6PtJ3x5nGGwtvxOYNK-DF0qKu5PqzLrb_hy4ew-0K0Vn6l8SaHdhYnJ6FJ3DTnS-64XQ3-9IPdxYlYQ
  priority: 102
  providerName: Directory of Open Access Journals
Title Risk of COVID-19 death in adults who received booster COVID-19 vaccinations in England
URI https://link.springer.com/article/10.1038/s41467-023-44276-x
https://www.ncbi.nlm.nih.gov/pubmed/38228613
https://www.proquest.com/docview/2915444538
https://www.proquest.com/docview/2915991397
https://pubmed.ncbi.nlm.nih.gov/PMC10791661
https://doaj.org/article/3ac0aac1dfad4f18b5bdd8cb5fa53c9e
Volume 15
WOSCitedRecordID wos001147728500020&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2041-1723
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000391844
  issn: 2041-1723
  databaseCode: DOA
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2041-1723
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000391844
  issn: 2041-1723
  databaseCode: M~E
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVPQU
  databaseName: AAdvanced Technologies & Aerospace Database (subscription)
  customDbUrl:
  eissn: 2041-1723
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000391844
  issn: 2041-1723
  databaseCode: P5Z
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/hightechjournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: AUTh Library subscriptions: ProQuest Central
  customDbUrl:
  eissn: 2041-1723
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000391844
  issn: 2041-1723
  databaseCode: BENPR
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Health & Medical Collection (ProQuest)
  customDbUrl:
  eissn: 2041-1723
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000391844
  issn: 2041-1723
  databaseCode: 7X7
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Biological Science
  customDbUrl:
  eissn: 2041-1723
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000391844
  issn: 2041-1723
  databaseCode: M7P
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/biologicalscijournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Publicly Available Content Database
  customDbUrl:
  eissn: 2041-1723
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000391844
  issn: 2041-1723
  databaseCode: PIMPY
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7RFiQuvB-BsgoSN7Cah53YJ0RLKyrBElWwWrhYftKoVVI221L-PbaT3dXy6IWLD7Et2RnP-POM_Q3AC50ZSvOUIFwYiTCxEgmLDdKJsP6pqCGBSmnyvhyP6XTKqsHh1g3XKhc2MRhq3SrvI9_JmOeNwU4_X599Rz5rlI-uDik0NmDLsyRk4epetfSxePZzivHwVibJ6U6Hg2VwGxXCOCsLdLm2HwXa_r9hzT-vTP4WNw3b0cHt_53IHbg1ANH4Tb9y7sI109yDG31qyp_3YXJUdydxa-O9j5PDtyhlsfZgMa6bOFB2dPGP4zZ25tI4c6ljh9U948Kq9YVQqu49jZ3vNCQLeQCfD_Y_7b1DQw4GpAhO58jqjGkmlZHuoKKtMwcZyYSWqVKFkG77KyWmWlljylJgaqQtBdXEJIol2FCVP4TNpm3MY4iNljpzp5OcEY0tZTIVVjOhrIOghaYkgnQhCa4GgnKfJ-OUh0B5TnkvPe6kx4P0-GUEL5d9znp6jitb73oBL1t6au3woZ1944Om8lyoRAiVaivcMFMqidSaKkmsILliJoLthVz5oO8dXwk1gufLaqepPvwiGtOe922YZ2EtI3jUr6blSHKH06hDVhHQtXW2NtT1mqY-Dmzg7vzuIH6RRvBqsSRX4_r3v3hy9TSews3MwTfvbEqLbdicz87NM7iuLuZ1NxvBRjktQ0lHsLW7P66ORsGbMQoK6MqKfHU11eGH6ssv22s3kg
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1JbxMxFH4qKQgu7MtAASPBCazO4pmxDwhBS9WoaYhQicrJeKURaKZk0u1P8RuxZ0kUlt564Dq2R16-t_jZ_h7Acx0bSpMoxSQzEpPUSiwsMViHwvqnoiatqZTGg3w4pPv7bLQCP7u3MP5aZacTa0WtS-Vj5Osx87wxxMnnm8Mf2GeN8qerXQqNBhY75uzEbdmq1_1Nt74v4njr_d7GNm6zCmCVkmiGrY6ZZlIZ6VxvbR3A4zQWWkZKZUI6hZ5LQrWyxuS5INRImwuqUxMqFhJDVeL-ewlWiQd7D1ZH_d3R53lUx_OtU0La1zlhQtcrUusiZxqxa5Jn-HTJAtaJAv7m3f55SfO3k9raAG7d-N-m7iZcb11t9LaRjVuwYorbcKVJvnl2B8YfJ9U3VFq08WHc38QRQ9q7w2hSoJqUpEInByVyBsE4g6CR2414TolF7WOh1KSJpVa-UZsO5S58upBB3YNeURbmASCjpY7d_ithqSaWMhkJq5lQ1jnZmaZpAFG38ly1FOw-E8h3Xl8FSChv0MIdWniNFn4awMt5m8OGgOTc2u88oOY1PXl4_aGcfuWtLuKJUKEQKtJWuG5GVKZSa6pkakWaKGYCWOtwxFuNVvEFiAJ4Ni92usgfMInClEdNHeZ5ZvMA7jfonfckcZ4odb5jAHQJ10tdXS4pJgc133kU5m4Tk0UBvOpEYNGvf8_Fw_OH8RSubu_tDvigP9x5BNdi56z60FqUrUFvNj0yj-GyOp5NqumTVsgRfLlo4fgFH5aTFA
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9QwFH4qZREX9iVQwEhwgqhZ7MQ5IAQdRoxaDSMEo6qX4JVGoKRMpttf49fxnGVGw9JbD1wTJ3pxvrfZz98DeKYjw3kcMp8mRvqUWekLS42vA2HdUVHDGiql6U46HvPd3WyyBj_7szCurLK3iY2h1pVya-SbUeZ4Yyjq56btyiImg-Hrgx--6yDldlr7dhotRLbN6TGmb_Wr0QD_9fMoGr77tPXe7zoM-IrRcO5bHWU6k8pIDMO1RbBHLBJahkolQqJxTyXlWllj0lRQbqRNBdfMBCoLqOEqxvdegIsp5piunHDC9hbrO455nVPandMJUOyaNlYJnaRPaZQm_smKL2xaBvwtzv2zXPO3PdvGFQ6v_8-TeAOudQE4edNqzE1YM-UtuNy25Dy9DdOPRf2NVJZsfZiOBn6YEe2CZFKUpKEqqcnxfkXQTRh0E5pgjuKYJpajj4RSRbvCWruHuiYpd-DzuXzUXVgvq9LcB2K01BFmZXHGNLU8k6GwOhPKYuidaM48CHsU5KojZnf9Qb7nTYFAzPMWOTkiJ2-Qk5948GLxzEFLS3Lm6LcOXIuRjlK8uVDNvuadhcpjoQIhVKitQDFDLpnUmivJrGCxyowHGz2m8s7O1fkSUB48XdxGC-W2nURpqsN2TObYZ1MP7rVIXkgSY3zKMaL0gK9gfEXU1Ttlsd-woIdBiqlNEnrwsleHpVz_nosHZ3_GE7iCGpHvjMbbD-FqhBGsW28Lkw1Yn88OzSO4pI7mRT173Gg7gS_nrRm_AJxxmnc
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Risk+of+COVID-19+death+in+adults+who+received+booster+COVID-19+vaccinations+in+England&rft.jtitle=Nature+communications&rft.au=Ward%2C+Isobel+L&rft.au=Robertson%2C+Chris&rft.au=Agrawal%2C+Utkarsh&rft.au=Patterson%2C+Lynsey&rft.date=2024-01-16&rft.eissn=2041-1723&rft.volume=15&rft.issue=1&rft.spage=398&rft_id=info:doi/10.1038%2Fs41467-023-44276-x&rft_id=info%3Apmid%2F38228613&rft.externalDocID=38228613
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2041-1723&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2041-1723&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2041-1723&client=summon